Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2023)
Avalo Therapeutics' (AVTX) quarterly Change in Receivables came in at -$38000.0 in Q3 2023, up 93.01% YoY from -$19687.6 in Q3 2022, and down 200.0% on a QoQ basis from $38000.0 in Q2 2023.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2023) Analysis & Trends
Avalo Therapeutics (AVTX) has 7 years of Change in Receivables data on file, last reported at -$38000.0 in Q3 2023.
- Quarterly Change in Receivables rose 93.01% year-over-year to -$38000.0 in Q3 2023, while the trailing twelve-month figure through Jun 2023 was -$506000.0 (up 85.85% YoY) and the FY2022 annual result came in at -$1.1 million, up 5.1% from the prior year.
- Change in Receivables declined to -$38000.0 in Q3 2023, from $38000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.1 million in Q3 2019 to a low of -$3.5 million in Q4 2019.
- A 5-year average of -$185725.5 and a median of -$123000.0 in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 798.99% in 2019, down 2419.57% in 2019.
- Tracing AVTX's Change in Receivables over 5 years: stood at -$3.5 million in 2019, then soared by 114.64% to $506000.0 in 2020, then sank by 174.11% to -$375000.0 in 2021, then tumbled by 45.07% to -$544000.0 in 2022, then jumped by 93.01% to -$38000.0 in 2023.
- The last three Change in Receivables figures came in at -$38000.0 (Q3 2023), $38000.0 (Q2 2023), and -$544000.0 (Q3 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Sep 30, 2022 | -544,000.00 |
| Jun 30, 2022 | -393,000.00 |
| Mar 31, 2022 | -123,000.00 |
| Dec 31, 2021 | -375,000.00 |
| Sep 30, 2021 | -2.69 Mn |
| Jun 30, 2021 | 990,000.00 |
| Mar 31, 2021 | 953,000.00 |
| Dec 31, 2020 | 506,000.00 |
| Sep 30, 2020 | -360,000.00 |
| Jun 30, 2020 | -164,000.00 |
| Mar 31, 2020 | 696,000.00 |
| Dec 31, 2019 | -3.46 Mn |
| Sep 30, 2019 | 2.10 Mn |
| Jun 30, 2019 | 141,892.00 |
| Mar 31, 2019 | -439,159.00 |
| Dec 31, 2018 | 149,017.00 |
| Sep 30, 2018 | -299,786.00 |
| Jun 30, 2018 | 477,970.00 |